AstraZeneca’s ALXN2350 Selected for CDE’s Rare Disease Drug Development Program

The Center for Drug Evaluation (CDE) in China has announced its intention to include AstraZeneca’s (AZ, NASDAQ: AZN) ALXN2350 in the patient-centered rare disease drug development pilot program, known as the Care Plan. The public has until December 23 to provide feedback on the notice.

ALXN2350: A Potential Treatment for BAG3 Mutant Dilated Cardiomyopathy
ALXN2350, currently at the project initiation stage, is being developed for the treatment of BAG3 mutant dilated cardiomyopathy, a rare and severe heart condition. The inclusion of ALXN2350 in the Care Plan signifies a significant step forward in the development of patient-centered therapies for rare diseases in China.-Fineline Info & Tech